Tevogen Bio (NASDAQ:TVGN) Shares Up 4.4% – What’s Next?

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) was up 4.4% on Tuesday . The stock traded as high as $4.16 and last traded at $4.06. 17,177 shares changed hands during mid-day trading, a decline of 20% from the average session volume of 21,579 shares. The stock had previously closed at $3.89.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Tevogen Bio in a research note on Friday, July 17th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Reduce” and a consensus target price of $100.00.

Tevogen Bio Stock Performance

The company’s 50-day moving average price is $7.91 and its 200 day moving average price is $9.60. The stock has a market capitalization of $18.44 million, a PE ratio of -0.95 and a beta of 0.20.

Tevogen Bio (NASDAQ:TVGN) last announced its quarterly earnings results on Friday, May 15th. The company reported ($1.61) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.64) by $1.03.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in TVGN. Bridgeway Capital Management LLC raised its position in shares of Tevogen Bio by 66.7% in the 3rd quarter. Bridgeway Capital Management LLC now owns 82,500 shares of the company’s stock worth $65,000 after acquiring an additional 33,000 shares in the last quarter. Deutsche Bank AG boosted its position in shares of Tevogen Bio by 304.1% during the fourth quarter. Deutsche Bank AG now owns 173,734 shares of the company’s stock valued at $57,000 after purchasing an additional 130,738 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its position in shares of Tevogen Bio by 126.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 273,694 shares of the company’s stock valued at $91,000 after purchasing an additional 152,572 shares in the last quarter.

About Tevogen Bio

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.